Jennifer Gershman, PharmD, CPh
Jennifer Gershman, PharmD, CPh, received her PharmD degree from Nova Southeastern University (NSU) College of Pharmacy in 2006 and completed a 2-year drug information residency. She served as a pharmacy professor at NSUâ€™s College of Pharmacy for 6 years, managed the drug information center, and conducted medication therapy management reviews. Dr. Gershman has published research on prescription drug abuse, regulatory issues, and drug information in various scholarly journals. Additionally, she received the Sheriffâ€™s Special Recognition Award for her collaboration with the Broward, Florida Sheriffâ€™s Office to prevent prescription drug abuse through a drug disposal program. She has also presented at pharmacist and physician continuing education programs on topics that include medication errors, prescription drug abuse, and legal and regulatory issues. Dr. Gershman can be followed on Twitter @jgershman2
Direct-to-physician marketing by pharmaceutical companies has sparked some controversy since evidence suggests it increases prescribing of the marketed products.2 In fact, between 2013 and 2015, about 1 in 12 physicians in the United States received opioid-related marketing.2 A recent study investigated the association of direct-to-physician marketing of opioid products by pharmaceutical companies and mortality from prescription opioid overdoses across the US.2 This cross-sectional study linked county-level information from August 2013 to December 2016 across the following 3 national databases: CDC opioid overdose mortality rates, Centers for Medicare & Medicaid Services, and the CDC prescribing rates.2 The type of marketing and physician practice location was also analyzed.
The study found that pharmaceutical companies spent almost $40 million in prescription opioid marketing to over 67,000 physicians across 2208 counties.2 Additionally, the Northeast areas of the US had the highest amount of opioid marketing, while the Midwest had the lowest.2 The study revealed that for each 3 additional payments made to physicians per 100,000 people in a county, opioid overdose deaths were up 18%.2 The most common type of marketing is generally meals provided for physicians, and there is a growing amount of evidence demonstrating that this leads to increased prescribing.2
It is important to keep in mind some of the study limitations. Cross-sectional studies can only provide associations and do not assess causality. Future studies are needed to evaluate the nature of drug marketing to physicians and the relationship with prescribing practices and opioid overdoses. The study also was unable to evaluate long-term trends and whether other drugs or substances (e.g. synthetic drugs, benzodiazepines, alcohol) contributed to the overdoses.2
This study raises important questions about whether opioid drug marketing to physicians is ethical while there is a growing opioid epidemic. Pharmacists can play an important role in educating physicians and patients regarding opioid medications, which includes safety considerations to encourage appropriate prescribing practices. All of the risks and benefits of opioid medications should be disclosed during pharmaceutical company presentations. Providing food during presentations should be avoided to ensure that all prescribing decisions are based upon evidence-based medication practices and the most up-to-date guidelines. Physicians and pharmacists should consult their state prescription drug monitoring programs when prescribing and dispensing opioid medications to prevent prescription drug abuse.
- Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017. MMWR Morb Mortal Wkly Rep 2019;67:1419–1427. doi: http://dx.doi.org/10.15585/mmwr.mm675152e1?rel=0" ?rel=0" .
- Hadland SE, Aguirre AR, Marshall BD, Cerda M. Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses. JAMA Netw Open. 2019;2(1):e186007. doi:10.1001/jamanetworkopen.2018.6007.